Sandoz' Sandimmune for recalcitrant psoriasis
Executive Summary
The immunosuppressive drug will be reviewed by FDA's Dermatologic Drugs Advisory Committee on Nov. 19. The committee will discuss Sandimmune (cyclosporine) in soft gelatin capsule and oral solutions (NDAs 50-695 and 50-696, respectively). Meeting is scheduled for the Holiday Inn Silver Spring Plaza (Plaza Ballroom), 8777 Georgia Ave., Silver Spring, Md. beginning at 9 a.m. The committee also will meet Nov. 20 in closed session to discuss pending INDs and NDAs.